Gastro Esophageal Reflux Clinical Trial
Official title:
Method of Early Diagnosis of Laryngopharyngeal Reflux in an Outpatient Appointment of an Otorhinolaryngologist
The investigator will issue a Patient Information Consent for the participant in the study. 1.Patients will be asked to complete the Reflux Symptom Index questionnaire. Clinical survey, medical history. 2. Objective methods for assessing the patient's condition: - examination of ENT organs. 3. Laboratory and instrumental research methods: Endoscopic laryngoscopy and video laryngoscopy, pH-metry, acoustic voice analysis. 4.Sociological method. 5. Subjective methods for assessing the condition of the larynx. 6. Аnalysis of the received data
The investigator will issue a Patient Information Consent for the participant in the study. 1.Patients will be asked to complete the Reflux Symptom Index questionnaire. Clinical survey, medical history 2. Objective methods for assessing the patient's condition: - examination of ENT organs: rhinoscopy, otoscopy, pharyngoscopy and laryngoscopy 3. Laboratory and instrumental research methods - Endoscopic laryngoscopy and video laryngoscopy. pH-metry: The collection of mucus from the laryngopharynx for the determination of acid-base values. Acoustic voice analysis: objective assessment of the voice condition 4.Sociological method: determination of lifestyle, nutrition, the presence or absence of bad habits. 5. Subjective methods for assessing the condition of the larynx - Questionnaires. 6. Аnalysis of the received data ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06025773 -
A Study to Compare PK/PD Characteristics and Safety Profiles Between AD-212-A and AD-2121
|
Phase 1 | |
Recruiting |
NCT06280664 -
Efficacy Of Hiatal Closure For GERD
|
||
Recruiting |
NCT05359965 -
Effect of CPAP on Abnormal Gastroesophageal Reflux and Lung Inflammation in IPF
|
N/A | |
Completed |
NCT04202692 -
Effect of a Combination Oral Formulation of Hyaluronic Acid, Chondroitin Sulphate and Magnesium Trisilicate in Patients With Gastro-Esophageal Reflux Disease Not Fully Satisfied With Their Treatment
|
N/A | |
Active, not recruiting |
NCT03646045 -
Transpyloric Feeding for Prevention of Micro-aspiration
|
||
Recruiting |
NCT06430047 -
Efficacy and Safety of EsoDuo®
|
Phase 4 | |
Completed |
NCT04268719 -
Near Focus NBI-Driven Artificial Intelligence for the Diagnosis of Gastro-Oesophageal Reflux Disease
|
||
Active, not recruiting |
NCT04614974 -
Initiation of Acid Suppression Therapy Prospective Outcomes for Laryngomalacia
|
Phase 1/Phase 2 | |
Terminated |
NCT05579444 -
Systems Biology of Gastrointestinal and Related Diseases
|
||
Recruiting |
NCT03868267 -
Japanese Upper GI Symptoms Compared With Iranian and Canadian Patients Presenting
|
||
Terminated |
NCT04028466 -
Effectiveness of Vonoprazan vs Omeprazole as Empiric Therapy for Gastroesophageal Reflux Disease (GERD) Patients Without Alarm Features
|
Phase 4 | |
Active, not recruiting |
NCT05371717 -
Domiciliary Management of Dental Erosion in Patients With GERD With Biomimetic Hydroxyapatite
|
N/A | |
Recruiting |
NCT05066594 -
Observational Registry of Transoral Incisionless Fundoplication (TIF) for Gastroesophageal Reflux Disease (GERD)
|
||
Completed |
NCT03476265 -
Lower Esophageal Sphincter (LES) Stimulation in Patients With Ineffective Esophageal Motility
|
N/A | |
Completed |
NCT03143608 -
GERD Treatment With Transoral Incisionless Fundoplication (TIF) Following Hiatal Hernia Surgery
|
N/A | |
Completed |
NCT04436159 -
Partial Versus Total Fundoplication in the Surgical Repair of Para-esophageal Hernia.
|
N/A | |
Completed |
NCT03258528 -
Effect of Right Lateral Position on Ventilated Preterm Neonates
|
N/A | |
Active, not recruiting |
NCT04500288 -
The Effect of Positional Therapy on Symptoms of Gastroesophageal Reflux Disease: A Prospective Pilot Study
|
N/A | |
Completed |
NCT04262648 -
Randomized Placebo-controlled Study of L. Reuteri NCIMB 30351 in GI Functional Disorders and Food Allergy in Newborns
|
N/A | |
Recruiting |
NCT04846010 -
Recovering Damaged Cells for Sequelae Caused by COVID-19, SARS-CoV-2
|
Phase 1/Phase 2 |